Goldman Sachs’s G1 Therapeutics, Inc. Common Stock GTHX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-210,623
| Closed | -$480K | – | 6150 |
|
|
2024
Q2 | $480K | Sell |
210,623
-237,338
| -53% | -$907K | ﹤0.01% | 4858 |
|
|
2024
Q1 | $1.94M | Buy |
447,961
+436,499
| +3,808% | +$1.52M | ﹤0.01% | 3885 |
|
|
2023
Q4 | $35K | Sell |
11,462
-4,829
| -30% | -$9.07K | ﹤0.01% | 5412 |
|
|
2023
Q3 | $23.5K | Sell |
16,291
-79,825
| -83% | -$154K | ﹤0.01% | 5341 |
|
|
2023
Q2 | $239K | Buy |
96,116
+34,826
| +57% | +$95.1K | ﹤0.01% | 5117 |
|
|
2023
Q1 | $164K | Sell |
61,290
-206,532
| -77% | -$992K | ﹤0.01% | 5360 |
|
|
2022
Q4 | $1.45M | Sell |
267,822
-64,008
| -19% | -$536K | ﹤0.01% | 4166 |
|
|
2022
Q3 | $4.14M | Sell |
331,830
-8,204
| -2% | -$93.7K | ﹤0.01% | 3301 |
|
|
2022
Q2 | $1.68M | Sell |
340,034
-105,103
| -24% | -$582K | ﹤0.01% | 4195 |
|
|
2022
Q1 | $3.38M | Buy |
445,137
+61,185
| +16% | +$580K | ﹤0.01% | 3732 |
|
|
2021
Q4 | $3.92M | Sell |
383,952
-303,752
| -44% | -$3.87M | ﹤0.01% | 3649 |
|
|
2021
Q3 | $9.23M | Buy |
687,704
+244,445
| +55% | +$3.98M | ﹤0.01% | 2808 |
|
|
2021
Q2 | $9.72M | Sell |
443,259
-128,536
| -22% | -$2.86M | ﹤0.01% | 2716 |
|
|
2021
Q1 | $13.8M | Sell |
571,795
-367,766
| -39% | -$8.55M | ﹤0.01% | 2272 |
|
|
2020
Q4 | $16.9M | Sell |
939,561
-16,440
| -2% | -$246K | ﹤0.01% | 2006 |
|
|
2020
Q3 | $11M | Buy |
956,001
+704,486
| +280% | +$11.6M | ﹤0.01% | 2236 |
|
|
2020
Q2 | $6.1M | Buy |
251,515
+44,237
| +21% | +$732K | ﹤0.01% | 2647 |
|
|
2020
Q1 | $2.28M | Buy |
207,278
+33,526
| +19% | +$626K | ﹤0.01% | 3206 |
|
|
2019
Q4 | $4.59M | Sell |
173,752
-83,940
| -33% | -$1.96M | ﹤0.01% | 3027 |
|
|
2019
Q3 | $5.87M | Buy |
257,692
+132,893
| +106% | +$4.19M | ﹤0.01% | 2730 |
|
|
2019
Q2 | $3.83M | Buy |
124,799
+9,746
| +8% | +$205K | ﹤0.01% | 3046 |
|
|
2019
Q1 | $1.91M | Buy |
115,053
+25,585
| +29% | +$485K | ﹤0.01% | 3668 |
|
|
2018
Q4 | $1.71M | Sell |
89,468
-705
| -0.8% | -$26.4K | ﹤0.01% | 3623 |
|
|
2018
Q3 | $4.71M | Buy |
90,173
+51,432
| +133% | +$2.8M | ﹤0.01% | 3031 |
|
|
2018
Q2 | $1.68M | Buy |
38,741
+18,499
| +91% | +$793K | ﹤0.01% | 3734 |
|
|
2018
Q1 | $750K | Sell |
20,242
-8,066
| -28% | -$215K | ﹤0.01% | 4234 |
|
|
2017
Q4 | $562K | Buy |
28,308
+19,923
| +238% | +$428K | ﹤0.01% | 4740 |
|
|
2017
Q3 | $209K | Sell |
8,385
-57,190
| -87% | -$1.06M | ﹤0.01% | 5724 |
|
|
2017
Q2 | $1.14M | Buy |
+65,575
| New | +$1.15M | ﹤0.01% | 4339 |
|
Goldman Sachs's GTHX Position: Q3 2024 in Review
Goldman Sachs sold out of G1 Therapeutics, Inc. Common Stock (GTHX) in Q3 2024, closing a stake of 210,623 shares — an estimated $480K sold.
Goldman Sachs first reported a position in GTHX in Q2 2017 and held it in 29 quarters. The position peaked at $16.9M in Q4 2020. 0 funds tracked by Wall St. Rank hold GTHX as of Q3 2024.
- Goldman Sachs reported no remaining G1 Therapeutics, Inc. Common Stock position as of Q3 2024 after selling out during the quarter.
- Goldman Sachs sold 210,623 G1 Therapeutics, Inc. Common Stock shares in Q3 2024, an estimated $480K.
- Goldman Sachs first reported a position in G1 Therapeutics, Inc. Common Stock in Q2 2017 and held it in 29 quarters.
- Goldman Sachs's G1 Therapeutics, Inc. Common Stock position peaked at $16.9M in Q4 2020.
- 0 funds tracked by Wall St. Rank held G1 Therapeutics, Inc. Common Stock as of Q3 2024.
Based on Goldman Sachs's 13F filing for Q3 2024, filed 14 Nov 2024.